TORONTO -- (MARKET WIRE) -- October 03, 2006 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today publication of studies demonstrating specific anti-tumor activity of its novel Ii-Key/HER-2/neu immunotherapeutic vaccine. The studies were performed in the laboratory of Dr. Costas Baxevanis in collaboration with scientists at Antigen Express, the immunotherapeutic division of Generex Biotechnology.
